{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T09:30:35Z","timestamp":1750411835242},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00066-023-02101-w","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T17:41:03Z","timestamp":1684258863000},"page":"694-696","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dosiseskalation mittels Brachytherapie zur Erh\u00f6hung der Organerhaltungsrate beim Rektumkarzinom","Dose escalation with brachytherapy to increase the organ preservation rate in rectal cancer"],"prefix":"10.1007","volume":"199","author":[{"given":"Elena","family":"Riggenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"L\u00f6ssl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Hemmatazad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"2101_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00032","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar\u00a0J, Patil\u00a0S, Gollub\u00a0MJ et al (2022) Organ preservation in patients with rectal adenocarcinoma treated with total Neoadjuvant therapy. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.00032","journal-title":"J Clin Oncol"},{"key":"2101_CR2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ijrobp.2013.12.012","volume":"88","author":"A Habr-Gama","year":"2014","unstructured":"Habr-Gama\u00a0A, Gama-Rodrigues\u00a0J, S\u00e3o\u00a0JGP et al (2014) Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 88:822\u2013828. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.12.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2101_CR3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(15)00120-5","volume":"16","author":"AL Appelt","year":"2015","unstructured":"Appelt\u00a0AL, Pl\u00f8en\u00a0J, Harling\u00a0H et al (2015) High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol 16:919\u2013927. https:\/\/doi.org\/10.1016\/S1470-2045(15)00120-5","journal-title":"Lancet Oncol"},{"key":"2101_CR4","doi-asserted-by":"publisher","first-page":"LBA3514","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3514","volume":"40","author":"LH Jensen","year":"2022","unstructured":"Jensen\u00a0LH, Risum\u00a0S, Nielsen\u00a0JD et\u00a0al (2022) Curative chemoradiation for low rectal cancer: primary clinical outcomes from a\u00a0multicenter phase II trial. J\u00a0Clin Oncol 40:LBA3514\u2013LBA3514. https:\/\/doi.org\/10.1200\/JCO.2022.40.17_suppl.LBA3514","journal-title":"J Clin Oncol"},{"key":"2101_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049119","author":"EM Hudson","year":"2022","unstructured":"Hudson\u00a0EM, Noutch\u00a0S, Brown\u00a0S et al (2022) A Phase\u00a0II trial of Higher RadiOtherapy Dose in the Eradication of early rectal cancer (APHRODITE): protocol for a\u00a0multicentre, open-label randomised controlled trial. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2021-049119","journal-title":"BMJ Open"},{"key":"2101_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14153665","volume":"14","author":"A Garant","year":"2022","unstructured":"Garant\u00a0A, Vasilevsky\u00a0CA, Boutros\u00a0M et al (2022) MORPHEUS phase\u00a0II\u2013III study: a pre-planned interim safety analysis and preliminary results. Cancers 14:1\u201312. https:\/\/doi.org\/10.3390\/cancers14153665","journal-title":"Cancers"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02101-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02101-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02101-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T16:04:05Z","timestamp":1687277045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02101-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":6,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2101"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02101-w","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"11 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.\u00a0Riggenbach, K.\u00a0L\u00f6ssl und H.\u00a0Hemmatazad geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}